Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism

Major bleeding is one of the most dangerous complications for patients undergoing anticoagulant treatment for VTE. Several clinical scores have been planned to identify patients at higher risk of bleeding, and most of them take into consideration the number of platelets in particular if lower than n...

Descripción completa

Detalles Bibliográficos
Autores: Di Micco, Pierpaolo, Monreal, Manuel|||0000-0002-0494-0767
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:252468
Acceso en línea:https://ddd.uab.cat/record/252468
https://dx.doi.org/urn:doi:10.2147/JBM.S234053
Access Level:acceso abierto
Palabra clave:Thrombocytopenia
Venous thromboembolism
Bleeding
Bleeding risk
Descripción
Sumario:Major bleeding is one of the most dangerous complications for patients undergoing anticoagulant treatment for VTE. Several clinical scores have been planned to identify patients at higher risk of bleeding, and most of them take into consideration the number of platelets in particular if lower than normal. Here we report the clinical experience made with the RIETE registry concerning anticoagulant treatment in the presence of different values of platelets and their related risk of bleeding.